CELLDEX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.3 USD | +0.11% |
|
-4.42% | -8.47% |
| 17/04 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
| 17/04 | Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise | MT |
Chart calendar Celldex Therapeutics, Inc.
c596442b42c77bcfd660eb108eac.--ZgN3-umgWUUNqNzVa2lJ4GUC2z5_D5xZIBekPBj1s.gp8SBTTn_XbhIO_8-AXY1vhfPnTxsN2B_KB3SG6C4mK1tjRnUuLqUtBikw~93700bfa06dcfc80d847415d09b47474
Upcoming events on Celldex Therapeutics, Inc.
Past events on Celldex Therapeutics, Inc.
| 11/03/2024 07:30 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 06/03/2024 12:40 am | TD Cowen Health Care Conference |
| 26/02/2024 05:31 pm | Q4 2023 Earnings Release |
| 25/02/2024 08:15 pm | American Academy of Allergy, Asthma & Immunology Meeting |
| 25/02/2024 12:35 am | American Academy of Allergy, Asthma & Immunology Meeting |
| 07/02/2024 07:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 29/11/2023 03:35 am | Evercore ISI HealthCONx Conference |
| 08/11/2023 01:50 am | World Itch Conference |
| 06/11/2023 06:30 pm | Barzolvolimab Phase 1b Study Results Call |
| 03/11/2023 01:31 am | Q3 2023 Earnings Release |
| 26/09/2023 10:30 pm | Cantor Global Healthcare Conference - Fireside Chat |
| 09/08/2023 01:31 am | Q2 2023 Earnings Release |
| 15/06/2023 06:30 pm | Annual General Meeting |
| 10/06/2023 08:15 pm | European Academy of Allergy and Clinical Immunology Congress |
| 10/06/2023 03:30 pm | European Academy of Allergy and Clinical Immunology Congress |
| 07/06/2023 06:30 pm | Jefferies Healthcare Conference |
| 05/05/2023 01:31 am | Q1 2023 Earnings Release |
| 30/03/2023 09:00 pm | H.C. Wainwright Autoimmune & Inflammatory Disease Conference |
| 01/03/2023 02:31 am | Q4 2022 Earnings Release |
| 27/02/2023 03:30 am | Barzolvolimab Phase 1b Study Update Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,57 3,15 13.43% | 7,42 4,20 76.62% | 4,65 5,34 -12.9% | 2,36 0,98 140.51% | 6,88 3,52 95.44% | 3,39 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | -155 -149 -3.58% | -186 |
|
EBIT Million USD | Released Forecast Spread | -55,0 -56,2 1.99% | -63,4 -53,2 -19.2% | -71,2 -69,4 -2.64% | -115 -112 -3.32% | -142 -149 4.52% | -177 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -50,9 -55,5 8.33% | -60,9 -52,4 -16.31% | -70,7 -70,4 -0.48% | -112 -114 1.73% | -141 -138 -2.7% | -172 |
|
Net income Million USD | Released Forecast Spread | -50,9 -55,5 8.33% | -59,8 -51,8 -15.41% | -70,5 -69,9 -0.92% | -112 -113 0.28% | -141 -138 -2.81% | -170 |
|
EPS USD | Released Forecast Spread | -3,51 -3,85 8.83% | -2,02 -1,77 -13.91% | -1,64 -1,62 -1.55% | -2,40 -2,38 -0.77% | -2,92 -2,81 -3.82% | -2,91 |
| Announcement Date | 26/03/20 | 29/03/21 | 28/02/22 | 28/02/23 | 26/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,33 1,04 -67.86% | 0,17 0,56 -68.93% | 0,16 0,40 -59.25% | 0,41 0,36 13.06% | 1,61 0,26 510.98% | 0,97 0,41 135.85% | 0,27 0,66 -59.39% | 1,52 0,58 160.06% | 4,13 0,86 382.87% | 0,82 | 0,86 | 2,28 | 0,90 | 0,92 |
|
EBITDA Million USD | Released Forecast Spread | -47,6 -42,3 -12.59% | -40,3 | -43,4 | -48,7 | -53,4 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -20,3 -18,6 -9.08% | -23,8 -21,3 -11.7% | -27,7 -23,8 -16.6% | -27,7 -28,0 0.91% | -27,9 -28,3 1.38% | -32,5 -30,3 -7.33% | -33,2 -33,6 1.18% | -41,2 -34,2 -20.72% | -35,1 -41,9 16.07% | -41,7 | -42,6 | -44,4 | -45,9 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -20,1 -20,0 -0.74% | -23,1 -20,7 -11.35% | -36,0 -23,8 -51.07% | -26,8 -28,0 4.46% | -26,5 -28,5 7.06% | -29,4 -29,9 1.8% | -30,5 -32,7 6.63% | -38,3 -33,1 -15.59% | -43,3 -39,6 -9.28% | -40,2 | -41,5 | -44,2 | -46,3 | |
|
Net income Million USD | Released Forecast Spread | -20,1 -19,5 -3.28% | -23,1 -21,2 -8.73% | -36,0 -21,8 -65.51% | -26,8 -27,7 3.45% | -26,5 -28,2 5.94% | -29,4 -29,8 1.55% | -30,5 -32,0 4.53% | -38,3 -32,8 -16.82% | -43,3 -39,5 -9.72% | -39,7 | -41,0 | -43,7 | -45,9 | |
|
EPS USD | Released Forecast Spread | -0,43 -0,41 -4.45% | -0,49 -0,45 -7.93% | -0,77 -0,47 -65.24% | -0,57 -0,58 1.16% | -0,56 -0,59 5.08% | -0,62 -0,63 1.9% | -0,65 -0,67 2.69% | -0,81 -0,68 -19.12% | -0,83 -0,74 -11.6% | -0,69 | -0,72 | -0,73 | -0,77 | |
| Announcement Date | 28/02/22 | 05/05/22 | 08/08/22 | 09/11/22 | 28/02/23 | 04/05/23 | 08/08/23 | 02/11/23 | 26/02/24 | - | - | - | - | - |
| Today 01:35 am | QIAGEN N.V.: Q1 2024 Earnings Release |
| 30/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 04:00 pm | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 04:00 pm | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 04:30 pm | ALKERMES PLC: Q1 2024 Earnings Release |
| 02/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Celldex Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CLDX Stock
- Calendar Celldex Therapeutics, Inc.
